Subtypes in BRCA-mutated breast cancer.

[1]  David Evans,et al.  Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study , 2018, The Lancet. Oncology.

[2]  Sean Ferree,et al.  PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Laenkholm,et al.  Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG , 2018, Acta oncologica.

[4]  E. Balslev,et al.  An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG) , 2018, Acta oncologica.

[5]  T. Nielsen,et al.  Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials , 2018, Acta oncologica.

[6]  Tonje G. Lien,et al.  Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up , 2017, Breast Cancer Research.

[7]  Daniel F. Hayes,et al.  20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.

[8]  T. Nielsen,et al.  High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial , 2016, Clinical Cancer Research.

[9]  O. Johannsson,et al.  Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers , 2016, British Journal of Cancer.

[10]  Mattias Rantalainen,et al.  Digital image analysis outperforms manual biomarker assessment in breast cancer , 2016, Modern Pathology.

[11]  A. Arance,et al.  Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.

[12]  Jane E. Carpenter,et al.  Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia , 2014, Breast Cancer Research.

[13]  K. Nielsen,et al.  Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. , 2014, European journal of cancer.

[14]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[15]  M. Larsen,et al.  Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics , 2014, Breast cancer : basic and clinical research.

[16]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Lubiński,et al.  Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Mouridsen,et al.  [Danish Breast Cancer Cooperative Group]. , 2012, Ugeskrift for laeger.

[21]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[22]  Päivi Heikkilä,et al.  Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[23]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[24]  Stephen Fox,et al.  Subtypes of familial breast tumours revealed by expression and copy number profiling , 2010, Breast Cancer Research and Treatment.

[25]  Mark T. W. Ebbert,et al.  A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[26]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[27]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[28]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[31]  M. Stratton,et al.  The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  P. Rosen,et al.  Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow‐up , 1977, Cancer.

[33]  John L Hopper,et al.  Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Sunil R. Lakhani,et al.  WHO classification of tumours of the breast , 2012 .

[35]  R. Prielipp,et al.  Clinical guidelines , 2003, BMJ.